Diagnostic-driven therapies face patient loss due to workflow gaps, new commercialization model proposed

The sponsored article from Diaceutics highlights that while diagnostic-driven therapies are being developed faster than ever, many patients who could benefit never receive them. The authors attribute this shortfall to complex diagnostic workflows, evolving testing protocols, and structural access barriers across care settings.

A specific example cited is advanced non‑small cell lung cancer, where targeted therapies exist. Diaceutics research indicates that about 64% of eligible patients do not receive the appropriate targeted treatment, and roughly 29% are lost even after a diagnostic test identifies the actionable biomarker.

To address these gaps, the piece proposes a new commercialization model aimed at strengthening diagnostic readiness, improving testing consistency and availability, educating healthcare providers, and directly connecting eligible patients with the right therapies.